Bioxytran Delays Annual 10-K Filing

Bioxytran ( (BIXT) ) has released a notification of late filing.

Bioxytran, Inc. has filed a Form 12b-25 indicating a delayed filing of its Form 10-K (Yearly Report) for the financial year ended December 31, 2025. The notification confirms that the company is late with its annual report, not a Form 10-Q (Quarter Report) or Form 20-F (Yearly Report).

The company cites its limited accounting staff and the timing of its year-end audit as the main reasons for missing the original deadline. During the final stages of the audit, the independent auditor proposed significant last-minute changes to the financial statement disclosures.

Because Bioxytran relies on a very small finance team, incorporating these revisions, validating the data, and obtaining final auditor review required more time than was available before the due date. The company states that filing on time would have required unreasonable effort and expense.

Bioxytran expects to submit its Form 10-K (Yearly Report) within the standard fifteen-day grace period allowed under SEC Rule 12b-25. Investors should therefore anticipate the annual report to be filed shortly after the original deadline, rather than a prolonged delay.

The company does not anticipate any significant change in its results of operations compared with the prior fiscal year, according to the notification. No preliminary figures are provided, and any expectations remain forward-looking and subject to revision once the audit is fully completed.

Bioxytran affirms that all other required periodic filings over the past 12 months have been made, signaling ongoing efforts to remain in compliance with reporting obligations. The notification is signed on March 31, 2026, by Chief Financial Officer Ola Soderquist, underscoring management’s responsibility for the delayed filing and the planned completion of the Form 10-K (Yearly Report).

More about Bioxytran

Average Trading Volume: 384,870

Technical Sentiment Signal: Sell

Current Market Cap: $4.44M

For an in-depth examination of BIXT stock, go to TipRanks’ Overview page.